Showing results (131-140 of 156) with videos related to

Sort By:
Pageof 16
Blood Cancer Journal|August 21, 2024
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trialGianluca Cavallaro, Anna Grassi, Chiara Pavoni, et al.
Leukemia|March 8, 2024
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE studyAnnalisa Chiappella, Beatrice Casadei, Patrizia Chiusolo, et al.
The Lancet. Haematology|February 3, 2019
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised studyFrancesca Bonifazi, Carlos Solano, Christine Wolschke, et al.
Haematologica|January 29, 2026
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trialFriedrich Stölzel, Matthias Stelljes, Dietrich Wilhelm Beelen, et al.
Bone Marrow Transplantation|July 2, 2026
Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patientsAttilio Olivieri, Giorgia Mancini, Jacopo Olivieri, et al.
American Journal of Hematology|May 26, 2022
Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trialDietrich W Beelen, Matthias Stelljes, Péter Reményi, et al.
The Lancet. Oncology|October 3, 2015
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trialAlessandro Rambaldi, Anna Grassi, Arianna Masciulli, et al.
Transplantation and Cellular Therapy|November 24, 2021
GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and CriticismsMichele Malagola, Nicola Polverelli, Vicky Rubini, et al.
Blood Advances|February 10, 2025
Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trialAnna Maria Raiola, Benedetto Bruno, Antonio Maria Risitano, et al.
American Journal of Hematology|June 6, 2025
Long-Term Outcome of Fanconi Anemia Patients From the Italian Registry on Behalf of the Marrow Failure Study Group of the AIEOP (Italian Association for Pediatric Haematology-Oncology)Erica Ricci, Francesca Bagnasco, Filomena Pierri, et al.
Pageof 16